Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.47 |
| ▸ | MGLL | Q99685 | 7/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12581439 | 0.89 | MGLL (0.54) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL22422923 | 0.88 | PTGS1 (0.38) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL14571358 | 0.87 | PTGS1 (0.41) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL19479888 | 0.87 | PTGS1 (0.61) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL14395731 | 0.86 | PTGS1 (0.37) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL27415275 | 0.86 | PTGS1 (0.40) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL12146979 | 0.85 | PTGS1 (0.64) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL3646852 | 0.85 | PTGS1 (0.64) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL26584960 | 0.85 | PTGS1 (0.44) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL12659454 | 0.84 | NAMPT (0.47) | PTGS1PTGS2MGLLFAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024085190-A1 | LIPID COMPOSITION AND METHOD OF DELIVERING THERAPEUTIC AGENT | FUJIFILM CORPORATION (JP) | 2024-04-25 | — | — | WO | disclosed |
| US-20230381337-A1 | MIR-145 MICELLES FOR MITIGATING ATHEROSCLEROSIS | NATIONAL INSTITUTES OF HEALTH | 2023-11-30 | — | — | US | disclosed |
| WO-2023215740-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230323028-A1 | ADHESIVE PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF | SKINOSIVE (FR) | 2023-10-12 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230256091-A1 | ANTI-TUMOR NANO ADJUVANT BASED ON VESICLE FORMED BY CROSS-LINKED BIODEGRADABLE POLYMER, PREPARATION METHOD THEREFOR AND USE THEREOF | SOOCHOW UNIVERSITY (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230256091-A1 | ANTI-TUMOR NANO ADJUVANT BASED ON VESICLE FORMED BY CROSS-LINKED BIODEGRADABLE POLYMER, PREPARATION METHOD THEREFOR AND USE THEREOF | SOOCHOW UNIVERSITY (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-11634448-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080199483-A1 | LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION | CONJUCHEM BIOTECHNOLOGIES INC., (CA) | 2008-08-21 | — | — | US | disclosed |
| US-20080176794-A1 | LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2008-07-24 | — | — | US | disclosed |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | GENENTECH, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080039532-A1 | Compounds For Specific Viral Target | ADVANCED DIAGNOSTICS AND DISCOVERY | 2008-02-14 | — | — | US | disclosed |
| US-7307148-B2 | Method for purification of albumin conjugates | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2007-12-11 | — | — | US | disclosed |
| US-7307148-B2 | Method for purification of albumin conjugates | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2007-12-11 | — | — | US | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070117153-A1 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634448-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | PTGS1 2107/4885PTGS2 2044/4885MGLL 830/4885 |
| US-20230323028-A1 | ADHESIVE PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF | ICAM1, CDH1, VCAM1 | PTGS1 1018/4885PTGS2 1388/4885MGLL 3691/4885 |
| US-20230256091-A1 | ANTI-TUMOR NANO ADJUVANT BASED ON VESICLE FORMED BY CROSS-LINKED BIODEGRADABLE POLYMER, PREPARATION METHOD THEREFOR AND USE THEREOF | GOT1, WEE1, HADH | PTGS1 784/4885PTGS2 1183/4885MGLL 2996/4885 |
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | BTD, IDUA, DNPEP | PTGS1 606/4885PTGS2 734/4885MGLL 147/4885 |
| US-20230381337-A1 | MIR-145 MICELLES FOR MITIGATING ATHEROSCLEROSIS | TGFB1, SENP5, SENP1 | PTGS1 2566/4885PTGS2 3401/4885MGLL 1054/4885 |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | CD47, FCGR2A, CD40 | PTGS1 1461/4885PTGS2 1646/4885MGLL 2474/4885 |
| US-20080199483-A1 | LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION | DNPEP, HM13, PELP1 | PTGS1 3139/4885PTGS2 3944/4885MGLL 3031/4885 |
| US-20080039532-A1 | Compounds For Specific Viral Target | HAVCR2, CNBP, SRRM2 | PTGS1 3148/4885PTGS2 3273/4885MGLL 4591/4885 |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | PTGS1 4626/4885PTGS2 4832/4885MGLL 4677/4885 |
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | PTGS1 1967/4885PTGS2 1927/4885MGLL 4187/4885 |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | ERBB2, EGFR, ERBB4 | PTGS1 2456/4885PTGS2 3386/4885MGLL 3202/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | PTGS1 4352/4885PTGS2 4342/4885MGLL 3971/4885 |
| US-20080176794-A1 | LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION | DNPEP, HM13, PELP1 | PTGS1 3139/4885PTGS2 3944/4885MGLL 3031/4885 |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | LNPEP, CSTB, ALB | PTGS1 1595/4885PTGS2 2320/4885MGLL 2872/4885 |
| US-20070117153-A1 | Molecular conjugate | CA12, FCGR2A, CA14 | PTGS1 2352/4885PTGS2 1788/4885MGLL 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.